Product Details
The Invesco Nasdaq Biotechnology ETF (Fund) is based on the Nasdaq Biotechnology Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The Fund and the Index are reconstituted annually in December and rebalanced quarterly in March, June, September and December.
Performance
| Index History (%) | YTD | 1Yr | 3Yr | 5Yr | 10Yr | Since Inception |
|---|---|---|---|---|---|---|
| Nasdaq Biotechnology Total Return Index (USD) | 1.58 | 8.28 | -1.34 | 5.51 | 6.62 | -4.07 |
| S&P Composite 1500 Biotechnology Total Return Index (USD) | 5.53 | 10.90 | 9.83 | 11.39 | 9.35 | 8.11 |
| Fund History (%) | ||||||
| Fund NAV | 1.53 | 8.15 | N/A | N/A | N/A | -4.16 |
| After Tax Held | 1.45 | 7.89 | N/A | N/A | N/A | -4.38 |
| After Tax Sold | 0.90 | 4.93 | N/A | N/A | N/A | -3.17 |
| Fund Market Price | 1.53 | 8.25 | N/A | N/A | N/A | -4.15 |
| Index History (%) | YTD | 1Yr | 3Yr | 5Yr | 10Yr | Since Inception |
|---|---|---|---|---|---|---|
| Nasdaq Biotechnology Total Return Index (USD) | 1.58 | 8.28 | -1.34 | 5.51 | 6.62 | -4.07 |
| S&P Composite 1500 Biotechnology Total Return Index (USD) | 5.53 | 10.90 | 9.83 | 11.39 | 9.35 | 8.11 |
| Fund History (%) | ||||||
| Fund NAV | 1.53 | 8.15 | N/A | N/A | N/A | -4.16 |
| After Tax Held | 1.45 | 7.89 | N/A | N/A | N/A | -4.38 |
| After Tax Sold | 0.90 | 4.93 | N/A | N/A | N/A | -3.17 |
| Fund Market Price | 1.53 | 8.25 | N/A | N/A | N/A | -4.15 |
This is a new Fund and has no full-year Fund performance to report as of most recent quarter end.
Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Performance data quoted represents past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than performance data quoted. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Fund performance reflects applicable fee waivers, absent which, performance data quoted would have been lower. After Tax Held and After Tax Sold are based on NAV. Returns less than one year are cumulative.
Please keep in mind that high, double-digit and/or triple-digit returns are highly unusual and cannot be sustained.
Growth of $10,000
Data beginning 10 years prior to the ending date of 03/31/2024. Fund performance shown at NAV.
An investor cannot invest directly in an index. The results assume that no cash was added to or assets withdrawn from the Index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Market Cap & Style Allocations
| Large-Cap Value | 16.91% |
| Large-Cap Blend | 18.34% |
| Large-Cap Growth | 5.31% |
| Mid-Cap Value | 7.61% |
| Mid-Cap Blend | 8.20% |
| Mid-Cap Growth | 12.09% |
| Small-Cap Value | 9.01% |
| Small-Cap Blend | 7.97% |
| Small-Cap Growth | 14.56% |
as of 04/12/2024 Top Holdings
Fund Holdings subject to change
| Ticker | Company | % of Fund |
|---|---|---|
| AMGN | Amgen Inc | 8.36 |
| GILD | Gilead Sciences Inc | 8.08 |
| VRTX | Vertex Pharmaceuticals Inc | 8.06 |
| REGN | Regeneron Pharmaceuticals Inc | 8.03 |
| MRNA | Moderna Inc | 4.39 |
| AZN | AstraZeneca PLC ADR | 4.39 |
| BIIB | Biogen Inc | 3.15 |
| ILMN | Illumina Inc | 2.21 |
| ALNY | Alnylam Pharmaceuticals Inc | 2.05 |
| BMRN | BioMarin Pharmaceutical Inc | 1.90 |
Distributions | Hide View All | Distribution Information
| Ex-Date | Record Date | Pay Date | $/ Share |
Ordinary Income | Short Term Gains | Long Term Gains | Return of Capital | Liquidation Distribution |
|---|---|---|---|---|---|---|---|---|
| 03/18/2024 | 03/19/2024 | 03/22/2024 | 0.04350 | 0.04350 | - | - | - | - |
| 12/18/2023 | 12/19/2023 | 12/22/2023 | 0.05262 | 0.05262 | - | - | - | - |
| 09/18/2023 | 09/19/2023 | 09/22/2023 | 0.04117 | 0.04117 | - | - | - | - |
| 06/20/2023 | 06/21/2023 | 06/23/2023 | 0.04526 | 0.04526 | - | - | - | - |
| 03/20/2023 | 03/21/2023 | 03/24/2023 | 0.03776 | 0.03776 | - | - | - | - |
| 12/19/2022 | 12/20/2022 | 12/23/2022 | 0.04188 | 0.04188 | - | - | - | - |
| 09/19/2022 | 09/20/2022 | 09/23/2022 | 0.03769 | 0.03769 | - | - | - | - |
| 06/21/2022 | 06/22/2022 | 06/30/2022 | 0.04264 | 0.04264 | - | - | - | - |
| 03/21/2022 | 03/22/2022 | 03/31/2022 | 0.03778 | 0.03778 | - | - | - | - |
| 12/20/2021 | 12/21/2021 | 12/31/2021 | 0.10511 | 0.10511 | - | - | - | - |
Distribution Information
Frequency Distribution of Discounts & Premiums
| Bid/Ask MidPoint Above NAV | |||||||
|---|---|---|---|---|---|---|---|
| Quarter Ending |
Days | 0.00- 0.25% |
0.26- 0.50% |
0.51- 0.99% |
1.00- 1.49% |
1.50- 1.99% |
≥2.00% |
| 03/31/2024 | 61 | 40 | 0 | 0 | 1 | 0 | 0 |
| 12/31/2023 | 63 | 29 | 0 | 0 | 0 | 0 | 0 |
| 09/30/2023 | 63 | 21 | 0 | 0 | 0 | 0 | 0 |
| 06/30/2023 | 62 | 20 | 0 | 0 | 0 | 0 | 0 |
| Year Ended 2023 | 250 | 91 | 0 | 0 | 0 | 0 | 0 |
| Bid/Ask Midpoint Below NAV | |||||||
|---|---|---|---|---|---|---|---|
| Quarter Ending |
Days | 0.00- 0.25% |
0.26- 0.50% |
0.51- 0.99% |
1.00- 1.49% |
1.50- 1.99% |
≥2.00% |
| 03/31/2024 | 61 | 18 | 1 | 0 | 1 | 0 | 0 |
| 12/31/2023 | 63 | 34 | 0 | 0 | 0 | 0 | 0 |
| 09/30/2023 | 63 | 42 | 0 | 0 | 0 | 0 | 0 |
| 06/30/2023 | 62 | 42 | 0 | 0 | 0 | 0 | 0 |
| Year Ended 2023 | 250 | 159 | 0 | 0 | 0 | 0 | 0 |
Fund Inception : 06/11/2021
Shareholders may pay more than net asset value when they buy Fund shares and receive less than net asset value when they sell those shares, because shares are bought and sold at current market prices. Performance data quoted represents past performance, which is not a guarantee of future results.
Shareholders may pay more than net asset value when they buy Fund shares and receive less than net asset value when they sell those shares, because shares are bought and sold at current market prices. Performance data quoted represents past performance, which is not a guarantee of future results.
Fund Documents
Risk & Other Information
Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.
There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund’s return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.
Investments focused in a particular industry, such as biotechnology, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.
Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.
The Fund is non-diversified and may experience greater volatility than a more diversified investment.
The Invesco Nasdaq Biotechnology ETF is not sponsored, endorsed, sold or promoted by the NASDAQ OMX Group, Inc. or its affiliates (NASDAQ OMX, with its affiliates, are referred to as the "Corporations"). The Corporations have no liability in connection with the administration, marketing or trading of the Invesco Nasdaq Biotechnology ETF. "NASDAQ®" is a registered trademark and is used under license.
The S&P Composite 1500® Biotechnology Index consists of all biotechnology stocks included in the S&P Composite 1500® Index.
United States
Canada (English)
United Kingdom
Isle of Man
Jersey
Guernsey
Australia
China
Hong Kong
Japan
Taiwan
Europe
Dubai